Comparison of the efficacy and safety of clinical trials of pemetrexed or gemcitabine combined with carboplatin in treatment of the elderly patients with advanced NSCLC
- VernacularTitle:培美曲塞与吉西他滨分别联合卡铂对老年晚期NSCLC的疗效对比及安全性评价
- Author:
Yanbo ZHU
;
Zhenxin WANG
;
Feng XIONG
;
Lingzhi WU
- Publication Type:Journal Article
- Keywords:
NSCLC;
aged;
pemetrexed;
gemcitabine;
carboplatin;
combination therapy;
treatment outcome
- From:
Chinese Journal of Biochemical Pharmaceutics
2014;37(4):145-147
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy and the safety of clinical trials of pemetrexed combined with carboplatin and gemcitabine with carboplatin in treating advanced NSCLC of the elderly patients.Methods A total of one hundred and twenty-eight elderly patients with advanced NSCLC were randomly divided into two groups(n=64).The PC group in which patients were treated with pemetrexed combined with carboplatin,and the GC group in which patients were treated with gemcitabine combined with carboplatin.The effects and the safety were assessed by the following indexes, treatment efficiency,side effects,LCSS. Results The treatment efficiency of the PC group and the GC group were 34.38% and 31.25% after chemotherapy.The difference was no statistically significant between two groups.The difference of LCSS was no statistically significant between two groups.Except hair loss,the incidences of nausea and vomiting,leukopenia,thrombocytopenia and neurotoxicity (grade III-IV )in the PC group (6.25%,3.13%,4.67%,7.81%)were significant lower than those in the GC group(17.18%,20.31%,15.63%,18.75%)(P<0.05).The 1-year and 2-year survival rates of the PC and GC groups were 46.2% VS 46.8% and 13.3% VS 12.5%,respectively,with a median survival of 12.1 VS 1 1.3 months,without a statistically significant difference between two groups.Conclusion PC and GC show similar efficacy for elderly NSCLC patients,however,the toxicities in PC patients are lower than those in GC patients.Thus,pemetrexed combined with carboplatin is an effective therapeutic regimen for advanced NSCLC in elderly patients.
